FDA AIDS announcements, first quarter 2005.The U.S. Food and Drug Administration distributed eight announcements on its AIDS list serve in January, February', and March 2005. Each one will be important for some of our readers. You can obtain all of these and any later announcements at the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome List Serve Archive page, http://www.fda.gov/oashi/aids/listserve/archive.html The eight announcements starting with the most recent are: * Important information about Sustiva (efavirenz efavirenz /ef·a·vi·renz/ (ef´ah-vi?renz) an antiretroviral, inhibiting reverse transcriptase; used in the treatment of HIV infection. e·fa·vir·enz n. ) and pregnancy, 2005-03-31 * Notice of important new drug interactions (Norvir or Kaletra), 2005-03-30 * Approval of Baraclude (entecavir) for treatment of chronic hepatitis B virus infection, 2005-03-30 * Updated guidelines for the use of antirctroviral agents in pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infection, 2005-03-24 * Pegasus and Copegus indications expanded to include treatment of hepatitis C and HIV coinfection, 2005-03-02 * Drug interaction warning: Saquinavir/ritonavir and rifampin, 2005-02-08 * FDA warning--unapproved home-use diagnostic test kits, 2005-02-07 * Tentative approval of copackaged antiretroviral for PEPFAR availability, 2005-01-26 You can also use the Archive page to subscribe to the FDA's AIDS list serve, if you want to be notified by email of future announcements when they go out. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion